Home › Lung Cancer › NCT05419076
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RecruitingPhase 2
A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Histologic diagnosis of small cell lung cancer * Radiographic diagnosis of up to 20 brain metastases on contrast-enhanced MRI * Age 18 and above * Performance status KPS 60-100/ECOG 0-2 * Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment * The patient or legally authorized representative is able to provide informed consent Exclusion Criteria: * Unable to undergo contrast-enhanced MRI brain * Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine * Pregnant or lactating women * Prior brain-directed radiotherapy * Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET/CT imaging, no more than 3 months before study enrollment
About the study
The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.
What is being tested
- Stereotactic Radiosurgery (radiation)
- Cerebrospinal fluid collection (procedure)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 62 · Started: Jun 10, 2022
Contact the study team
- Luke Pike, MD · Phone: 201-775-7604
- Brandon Imber, MD · Phone: 631-212-6346
Official record on ClinicalTrials.gov — NCT05419076
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.